Last updated: June 1, 2026
POKONZA is a prescription pharmaceutical product. Public supplier intelligence requires mapping (1) the FDA/marketing labeler and commercial manufacturer(s), (2) the listed suppliers of drug substance and intermediates used in the registered manufacturing process, and (3) secondary packaging and distribution partners. No source-quality supplier roster is provided in the information available in this session, so a complete and accurate supplier list cannot be produced.
What company makes POKONZA in the US and who is the labeler?
A precise supplier answer depends on the FDA-registered labeler/manufacturer shown on the product’s US listing (e.g., DailyMed “Labeler Name” and “Manufacturer” fields) and the product’s marketing application type. Supplier names must be tied to those authoritative fields.
What are the drug substance and intermediate suppliers for POKONZA?
Drug substance (API) and intermediate suppliers are typically identified in three ways: (1) DMF-linked manufacturers on FDA records, (2) contract manufacturing organization (CMO) listings tied to the application, and (3) disclosed supplier names within regulatory submissions, packaging labels, or authenticated supply-chain disclosures. Without those records, a definitive supplier list for the API is not producible.
Which CDMOs or API manufacturers typically supply drugs like POKONZA?
Generic CDMO/API vendor categories do not substitute for an evidence-linked supplier list for POKONZA.
What contract manufacturers produce POKONZA dosage forms and packaging?
Packaging suppliers and contract manufacturers are identified via product label “Manufactured for/Distributed by” language and, where applicable, NDC labeler/manufacturers. A supplier list must reflect the specific dosage form (tablet, capsule, suspension, injection) and strength.
What Orange Book listings reveal about POKONZA supply chain?
Orange Book listings identify the approved drug product(s), application numbers, and patent coverage, which can help connect to manufacturing sites and sometimes to the responsible NDA/ANDA holder. Supplier names for production still require FDA listing and labeler confirmation.
Which generic or biosimilar challengers could disrupt POKONZA supply?
Disruption risk is tied to competitors’ ANDA filings and launch timing, not to unverified supplier rumors. Without FDA filing details for POKONZA’s active ingredient, no credible generic risk map can be built.
What patent estate controls POKONZA manufacturing methods and formulations?
Method-of-manufacture and formulation patents can constrain CMO process development and raw-material selection. Without the specific patent numbers and assignees for POKONZA, supplier constraints cannot be quantified.
When does POKONZA lose exclusivity and what that means for suppliers?
Exclusivity timelines depend on reference product approval date, exclusivity grants (marketing exclusivity, pediatric, orphan, NCE), and patent expiration events. Without the relevant regulatory dates for POKONZA, supplier shift timing is not actionable.
Key Takeaways
- A complete, accurate supplier roster for POKONZA requires FDA-labeler and manufacturer identification plus (where available) DMF-linked API/intermediate suppliers.
- The available information in this session is insufficient to produce an evidence-linked list of POKONZA suppliers.
- Any names provided without those authoritative fields would be speculative and not suitable for high-stakes supplier, licensing, or litigation decisions.
FAQs
- How do I identify the US manufacturer for POKONZA? From the product’s FDA listing (DailyMed/NDC labeler and manufacturer fields) tied to the exact dosage form and strength.
- Do POKONZA API suppliers appear on the product label? Often not directly; they are typically linked through DMFs, application manufacturing disclosures, or regulatory filings.
- Can patent listings predict which CMOs can make POKONZA? Yes, if method-of-manufacture/formulation claims and their assignees are mapped to the manufacturing process and sites used by the reference product.
- What’s the best source to validate POKONZA contract manufacturers? FDA-registered manufacturing site information and the label “Manufactured for/Distributed by” language for the specific NDC.
- Do generic launches change POKONZA supplier risk? Supplier leverage often shifts when ANDA approvals and launches begin, but this requires filing and approval timing for the relevant active ingredient.
References
No cited sources were provided in the information available in this session.
